TG THERAPEUTICS, INC.TGTXEarnings & Financial Report
Nasdaq
TGTX Q3 2025 Key Financial Metrics
Revenue
$161.7M
Gross Profit
$133.6M
Operating Profit
$29.4M
Net Profit
$390.9M
Gross Margin
82.6%
Operating Margin
18.2%
Net Margin
241.7%
YoY Growth
92.8%
EPS
$2.43
Financial Flow
TG THERAPEUTICS, INC. Q3 2025 Financial Summary
TG THERAPEUTICS, INC. reported revenue of $161.7M for Q3 2025, with a net profit of $390.9M (241.7% margin). Cost of goods sold was $28.1M, operating expenses totaled $104.3M.
Key Financial Metrics
| Total Revenue | $161.7M |
|---|---|
| Net Profit | $390.9M |
| Gross Margin | 82.6% |
| Operating Margin | 18.2% |
| Report Period | Q3 2025 |
TG THERAPEUTICS, INC. Annual Revenue by Year
TG THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $329.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $329.0M |
| 2023 | $233.7M |
| 2022 | $2.8M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.0M | $63.5M | $73.5M | $83.9M | $108.2M | $120.9M | $141.1M | $161.7M |
| YoY Growth | 54184.0% | 713.5% | 357.0% | -49.4% | 146.0% | 90.4% | 92.1% | 92.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $329.6M | $373.3M | $401.2M | $586.0M | $577.7M | $656.7M | $702.6M | $1.03B |
| Liabilities | $169.1M | $213.2M | $223.6M | $393.9M | $355.3M | $419.4M | $426.2M | $417.8M |
| Equity | $160.5M | $160.1M | $177.6M | $192.2M | $222.4M | $237.3M | $276.4M | $607.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-13.2M | $-8.2M | $5.5M | $-12.2M | $-25.6M | $-28.7M | $7.4M | $-23.2M |